简介：AbstractThe year 2020 is an extremely unusual year. The world lost more than one million lives due to the attack of COVID-19. Economic production has been greatly reduced, and daily activities are largely restricted. Luckily the work of Chinese Journal of Traumatology (CJTEE) has not been adversely affected. 2020 is a harvest year for the journal, which (1) was included in the high-quality academic journals by China Association for Science and Technology; (2) cover of each issue is newly designed; (3) submission increased by about 60% with more countries and regions covered; (4) usage in the ScienceDirect database exceeded a million; (5) the CiteScore rises to more than 2.0 the first time. This study reviewed the articles published in the year 2020 by CJTEE.

简介：AbstractTrauma is the leading cause of death in people under the age of 45 years, and it has gained wide attention from academics worldwide. Therefore, more and more studies have reported on trauma and related fields in recent decades. In 2019, Chinese Journal of Traumatology (CJTEE) published 69 articles covering traffic medicine, wound healing, bone trauma, emergency care, and other hot topics of traumatology. Here we reviewed a series of articles published in CJTEE on the topics mentioned above, try to give a brief introduction of progress in trauma field.

简介：Objective:Population-basedcancerregistrationdatain2010werecollected,evaluatedandanalyzedbytheNationalCentralCancerRegistry(NCCR)ofChina.Cancerincidentnewcasesandcancerdeathswereestimated.Methods:Therewere219cancerregistriessubmittedcancerincidenceanddeathdatain2010.AlldatawerecheckedandevaluatedonbasisofthecriteriaofdataqualityfromNCCR.Total145registries’datawerequalifiedandacceptedforcancerstatisticsin2010.Pooleddatawerestratifiedbyurban/rural,area,sex,agegroupandcancersite.Cancerincidentcasesanddeathswereestimatedusingage-specificratesandnationalpopulation.Thetoptencommoncancersindifferentgroups,proportionandcumulativeratewerealsocalculated.Chinesecensusin2000andSegi’spopulationwereusedforage-standardizedincidence/mortalityrates.Results:All145cancerregistries(63inurbanand82inrural)coveredatotalof158,403,248population(92,433,739inurbanand65,969,509inruralareas).Theestimatesofnewcancerincidentcasesandcancerdeathswere3,093,039and1,956,622in2010,respectively.Themorphologyverifiedcases(MV%)accountedfor67.11%and2.99%ofincidentcaseswereidentifiedthroughdeathcertificationsonly(DCO%)withmortalitytoincidenceratio(M/I)of0.61.Thecrudeincidenceratewas235.23/100,000(268.65/100,000inmales,200.21/100,000infemales),age-standardizedincidenceratesbyChinesestandardpopulation(ASIRC,2000)andbyworldstandardpopulation(ASIRW)were184.58/100,000and181.49/100,000withthecumulativeincidencerate(0-74yearsold)of21.11%.ThecancerincidenceandASIRCwere256.41/100,000and187.53/100,000inurbanareaswhereasinruralareas,theywere213.71/100,000and181.10/100,000,respectively.ThecrudecancermortalityinChinawas148.81/100,000(186.37/100,000inmalesand109.42/100,000infemales),age-standardizedincidenceratesbyChinesestandardpopulation(ASMRC,2000)andbyworldstandardpopulation(ASMRW)were113.92/100,000and112.86/100,0

简介：无

简介：

简介：The5thAnnualScientificSessionofCardiologyinSouthChinawasheldfromApril3—7.2003inGuangzhou.Aseminar——“TheFrontlineProblemsandNewViewpointsinCardiologyinRecentTimes”washeldatthesametime.MorethanonethousandcardiologyspecialistscamefromsouthandmiddleChinatoparticipateinthemeetingand135paperswere

简介：AbstractTreatment of multiple myeloma (MM) has advanced dramatically in the past two decades. However, under the conditions of the COVID-19 pandemic, treatment strategies have been modified accordingly. Numerous novel agents, updated trials, and major advances in myeloma have been reported in the American Society of Hematology 2020 annual meeting, either for transplant-eligible or ineligible patients. Hot topics such as the significance of autologous stem cell transplantation (ASCT), development of novel agents, and chimeric antigen receptor-T (CAR-T) cells have been widely discussed. The triplet regimen bortezomib, lenalidomide, and dexamethasone (VRd) is recommended as the standard first-line treatment, and the addition of a fourth drug improves efficacy and survival. The value of ASCT remains undoubtful, even in the era of quadruplet induction. Dual-drug maintenance, including proteasome inhibitors and immunomodulatory drugs, overcomes unfavorable outcomes in high-risk patients. For relapsed/refractory myeloma (RRMM) patients, novel agents such as selinexor and venetoclax are superior. CAR-T cells and other cell-surface-targeted therapies also appear promising.

简介：Thereversetranscriptase(RT)proteinofhepatitisBvirus(HBV)hasbeensuccessfullyexpressedbyrecombinanttechnologyinEschericahiacoli(E.coli).Inthisstudyweaimedtodevelopasemi-quantitativeassayforthestudyofHBVRTproteinusingthissystem.CompleteHBVpolymerasegenefromawildtypevirus(rt306P)andthepolymerasegenefromamutant,withrt306Psubstitutedbyserine(rtP306S)wereseparatelyfusedtothemaltosebindingprotein(MBP)geneandexpressedinE.colirespectively.TheexpressionlevelsofHBVpolymerasegenesfromthewildtypevirusanditscounterpartmutantatrt306werecompared.Whentheseproteinsweresemi-quantifiedbyWesternblottingusingrabbitanti-TPserum,thertP306SmutantshoweddecreasedexpressionofMBP-HBVpolymerase.Bythismethod,wehaveshownthattheexpressionlevelofHBVRTcouldbeaffectedbysubstitutionsinitsaminoacidsequences,andthismethodcouldbeusedtostudythecharacteristicsofHBVRTprotein.

简介：

简介：TheannualmeetingoftheHeartFailureAssociationofESCinLisbon,inJune2005,wasexceptionallysuccessful.Thereweremanyveryinterestingpresentationsandworkshopswiththeuniquetitle:StatinsinheartfailureCholesterol-loweringisnottheonlygoalHeartfailure(HF)isaprogressivediseasewithcoronaryarterydisease(CAD)asthemostoftenunderlyingetiology.TreatmenttopreventprogressionofheartfailurehasbeentargetedtoreversetheconsequencesofHFandtoalessextentthecause-theatheroscleroticplaqueitself.Ontheaverage50%ofpatientswithheartfailurearetreatedwithlipidintervention.Lipid-loweringtreatmentwithstatinsclearlyreducesmorbidityandmortalityofpatientswithdocumentedCAD.SincetheprevalentetiologyofheartfailureisCAD,itspreventionmayreduceheartfailureprogression.However,recentstudiessuggestthatpleiotropiceffectsofstatinsaremoreimportantthantheinfluencerelatedtotheircholesterolloweringmechanism.Furthermoreitissuggestedthatlowlevelsofcirculatinglipoproteinsandcholesterolmaybeindependentpredictorsofimpairedoutcomeinpatientswithheartfailure.Therearesomepossibleexplanationsforthisfinding.Highlevelsofcholesterolcanbebeneficialtoheartfailurepatients;cholesterol-richserumlipoproteinsareabletomodulateinflammatoryimmunefunctionbecausetheybindanddetoxifybacteriallipopolysaccharide,averystrongstimulatorofthereleaseofproinflammatorycytokinesthatpromoteheartfailureprogressionanddeath.SocurrentrecommendationsstronglyemphasizethattheaimoftreatmentofHFisnottolowercholesterol.

简介：AbstractObjective:In 2015, the Chinese Pancreatic Association of the Chinese Society of Surgery of the Chinese Medical Association launched a national multicenter online system for registration of surgical treatment of pancreatic cancer in China, called China Pancreas Data Center (CPDC). With continued effort, the CPDC has developed over time. Herein, we report the general results of the CPDC from January 2016 to January 2020 to present the real-world situation of surgical treatment of pancreatic cancer in China.Methods:The data of the CPDC from January 2016 to January 2020 were retrieved and analyzed in this real-world study, including the data on patient demographics, comorbidities, diagnostic modalities, neoadjuvant treatment, surgical procedures, postoperative complications and treatment, pathological examinations, postoperative adjuvant treatment, survival, and risk factors.Results:A total of 13,595 cases from 70 centers in 28 provinces were retrieved for analysis. This study reported the largest cohort of patients who underwent surgical treatment for pancreatic cancer in China to date. More cases were derived from the Eastern regions, among which Shanghai, Beijing, and Zhejiang ranked in the top three. The peak age of the patients ranged from 60 to 69 years. The ratio of males to females was 1.5:1. Overall, 64.3% of the tumors were located in the head and neck of the pancreas, and 35.7% in the body and tail of the pancreas. Of the patients, 23.0% underwent positron-emission tomography-computed tomography, 21.6% underwent endoscopic ultrasound, and 4.8% underwent preoperative biopsy. Two percent of the patients underwent neoadjuvant treatment, while 68.9% underwent R0 surgical resection (margin free of tumor cells). Of the latter, 78.6% of the operations were open procedures, 12.6% were laparoscopic procedures, 2.9% were robotic procedures, and 3.7% were converted to open procedures. The in-hospital mortality rate after surgery was 0.4%. The incidence of grade 2 and grade 3 postoperative pancreatic fistulas was 25.5% and 2.5%, respectively. The incidence of complications based on the Clavien-Dindo classification was 17.9% of grade II, 4.3% of grade IIIa, 1% of grade IIIb, and 0.6% of grade IV. Of the patients, 28.9% underwent postoperative adjuvant chemotherapy. The 1-year, 2-year, and 3-year overall survival of these patients were 77%, 51%, and 38%, respectively. In the 8542 patients who underwent R0 resection, the 1-year, 2-year, and 3-year overall survival and disease-free survival were 77% , 54%, and 43%, and 68%, 49%, and 41%, respectively. The factors related to the prognosis of these patients were also identified after uni-and multi-variate analyses.Conclusion:The surgical quality, safety, and long-term survival of the patients in CPDC are similar to those of international high-volume pancreatic centers. However, neoadjuvant and postoperative adjuvant chemotherapy should be improved.

简介：BACKGROUND:Ithasbeenreportedthatperoxisomeproliferator-activatedreceptorγ(PPARγ)ishighlyexpressedinlungcancer,coloncancer,andgastriccancer,aswellasothertumors.OBJECTIVE:TostudyexpressionofPPARγinpituitaryadenomasandanalyzetheroleofPPARγinhormonaltypingofpituitaryadenomas.DESIGN,TIMEANDSETTING:Semi-quantitativeimmunohistochemistryofpathologicalspecimens.TheexperimentwasconductedattheDepartmentofNeurosurgery,WuxiSecondHospitalAffiliatedtoNanjingMedicalUniversitybetweenJanuary2002andMay2005.MATERIALS:Surgicalresectionsamplesofpituitaryadenomasfrom38cases(18maleand20female)wereanalyzed.Eightcasesweredeterminedtobeinvasivepituitaryadenomasand30caseswerenon-invasivepituitaryadenomas.Hormonalclassificationofthetypesofpituitaryadenomasrevealedsomatotrophicadenomasinsixcases,corticotrophicadenomainfivecases,prolactinomasin13cases,multi-hormonesecretingadenomasinsixcases,andeightcasesofadenomawithoutalteredendocrinefunction.Fiveautopsyspecimenswerecollectedduringthesameperiodfrompatientsofmatchingagethatdiedfromunrelateddiseasesandwereincludedasnormalanteriorpituitarycontrols.METHODS:Cellcountsforpositiveimmunohistochemicalsignalswererecordedfromhistopathologicalsections.Thepercentageofpositivecellswasreportedasasemi-quantitativeanalysis.MAINOUTCOMEMEASURES:TherateofPPARγpositivecellsindifferenttypesofadenomawasbasedonhormonallevelsandinvasivenessofpituitarytumorcells.RESULTS:AlltumorbiopsiesweredeterminedtoexpressPPARγTherateofPPARγ-positivecellsrangedbetween8%-65%inthepituitaryadenomas.Accordingtohormonaltype,PPARγexpressiondidnotvarybetweenthegroups.Inaddition,therewasnosignificantdifferenceinPPARγexpressionbetweenthenon-invasiveandinvasivepituitaryadenomas.CONCLUSIONS:HumanpituitaryadenomasexpressPPARγ,andthisexpressionisunrelatedto